IGF1R and cancer: A better knowledge may have important implications, considering that in clinical trials the target therapy with inhibition of IGF-1R is often inadequate to inhibit cancer progression [25], probably because the mitogenic signal might be propagated by the IR, an alternative pathway to the inhibited IGF-1R.